Work

Induction de maladies inflammatoires systémiques sous traitement par dupilumab

Year: 2024
Type: dissertation
Study design: Observational Study
Abstract: Dupilumab is a treatment that has been authorized for market use in France since 2018. It is indicated for moderate to severe atopic dermatitis, moderate to severe asthma, nasal-sinus polyposis, eosinophilic esophagitis, and nodular prurigo. It is a monoclonal antibody targeting the alpha subunit of the interleukin (IL)-4 receptor, thereby blocking the signaling induced by IL-4 and IL-13, and consequently, the type 2 immune response. Since its market approval, several cases of de novo development or relapse of inflammatory diseases under dupilumab treatment have been described in the literature. We conducted a multicenter retrospective study through a call for observations to collect data from patients presenting with a systemic inflammatory disease that appeared or relapsed following dupilumab treatment. We then performed a pharmacovigilance study using the Vigibase database (the global database of the WHO) to confirm or not confirm certain pharmacovigilance signals. We studied the reporting odds ratios (ROR) of various suspected pathologies, considering a pharmacovigilance signal as any condition with an ROR greater than 1. The pathologies observed in the call for observations that also showed a pharmacovigilance signal in the Vigibase database study included eosinophilic granulomatosis with polyangiitis, seronegative arthritis, cutaneous granulomatoses, sarcoidosis, giant cell arteritis, Addison’s disease, Sjögren’s syndrome, and systemic lupus erythematosus. Dupilumab thus appears to be associated with the de novo onset or relapse of these systemic inflammatory diseases, although a causal link cannot be definitively established with the methodology used. The recommended management approach for a systemic inflammatory disease under dupilumab includes discontinuing dupilumab and initiating treatment with systemic corticosteroids, possibly combined with another immunosuppressant or immunomodulator. However, the long-term outcomes of these diseases developed under dupilumab and the specific patient populations at risk for developing them remain unknown. Ongoing surveillance and case reporting to pharmacovigilance will be crucial to address these questions in the future.
Source: HAL
Author: Tisseau des Escotais, Jeanne
Language: English
Subfield: Toxicology
Open Access status: green
OpenAlex ID: W6982404716
Cites: 40
Cited by:
Related to: 10